Cearna Aesthetics Patents Revolutionary Aesthetics Anti-Bruising Technology
Sep. 11, 2018
SAN DIEGO--(BUSINESS WIRE)--Sep 11, 2018--Cearna Aesthetics, an aesthetics company developing plastic surgery and dermatology products, has announced that the U.S. Patent and Trademark Office granted a patent protecting its groundbreaking OcuMend ® hydrogel technology.
Cearna Aesthetics’ novel technology reduces bruising, pain, swelling and inflammation. OcuMend deploys arnica in a topical gel pad with 50 times the potency of other arnica gels. U.S. Patent No. 10,022,335 protects Cearna Aesthetics’ innovative manufacturing procedure for its high-potency arnica topical gel pad delivery system.
OcuMend is designed for cosmetic injectable procedures such as Juvéderm ®, Restylane ® and Botox ® and cosmetic surgery procedures such as rhinoplasty and blepharoplasty. According to the International Society of Aesthetic Plastic Surgery, 23 million aesthetic procedures were performed worldwide in 2016. On average, 66% of dermal filler patients bruise, based on 2,967 patients and 28 studies reported in Juvéderm and Restylane package inserts. According to the American Society for Aesthetic Plastic Surgery, average surgical recovery time is 1-2 weeks for most cosmetic surgery procedures.
“I congratulate Cearna Aesthetics on receiving this important patent,” says Dr. Tina Alster. “OcuMend is unparalleled in its ability to reduce bruising and swelling after a wide variety of aesthetic procedures. As such, it has quickly become an indispensable addition to the post-treatment regimen that is prescribed to my patients.”
“Too many patients are afraid that bruising and swelling from dermal fillers will embarrass them when their husband, family or friends see it,” says Dr. Josephine Polich, inventor of OcuMend and founder and CEO of Cearna Aesthetics. “Our goal is to virtually eliminate bruising and swelling for filler patients and reduce recovery by 50% for the vast majority of surgical patients. We believe this will have a tremendous positive impact on the aesthetics market.”
In a clinical study in Ophthalmic Plastic and Reconstructive Surgery (2017), Drs. Stuart Seiff, Wendy Lee and William Mack reported 52% of rhinoplasty and blepharoplasty patients recovered an average of seven days faster with OcuMend. Subsequent to this study, Cearna Aesthetics has tripled the OcuMend dosage for improved results.
“Congratulations to Cearna Aesthetics for getting a patent on this revolutionary invention,” says Dr. Jason Bloom. “I have been using OcuMend for years because it is by far the most effective product available to reduce bruising and swelling after dermal fillers and plastic surgery. Patients need OcuMend.”
About Cearna Aesthetics
Cearna Aesthetics is proud to provide the only patented, scientifically proven solution for bruising, pain, swelling and inflammation in the medical aesthetics industry. To date, Cearna Aesthetics has sold over 80,000 OcuMend gel pads with a money-back guarantee and a 99.9% satisfaction rate.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180911005224/en/
CONTACT: Cearna Aesthetics
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: SURGERY HEALTH ALTERNATIVE MEDICINE BIOTECHNOLOGY PHARMACEUTICAL OTHER HEALTH RETAIL COSMETICS OTHER SCIENCE SCIENCE GENERAL HEALTH
SOURCE: Cearna Aesthetics
Copyright Business Wire 2018.
PUB: 09/11/2018 10:00 AM/DISC: 09/11/2018 10:01 AM